Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DIVALPROEX SODIUM

All products: general benefit

Other products in the same Health Canada class (N03A, N03AG) — coverage varies; not interchangeable

  • Valproate (Depakene): general benefit
  • Valproic acid (Depakene): general benefit, Not a benefit
  • Vigabatrin (Vigabatrin for Oral Solution, USP 500mg): limited Use 136, Listing status unconfirmed
  • Carbamazepine (Tegretol): general benefit, Limited Use, Not a benefit, Listing status unconfirmed
  • Clonazepam (Rivotril): general benefit
  • Ethosuximide (Zarontin): general benefit

14 more in the class list below

Epival · DIN 00596426 · 250mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Epival (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Epival · DIN 00596426 Manufacturer: BGP Pharma ULC; listing date 1996-10-01 Health Canada: Marketed since 2016-07-22 · brand EPIVAL · ATC N03AG01 VALPROIC ACID · form Tablet (delayed-release) · route Oral · ingredients VALPROIC ACID (DIVALPROEX SODIUM) 250 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2767 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5677 · Verify on the e-Formulary ↗ (DIN 00596426)

Source record
DIN 00596426: Epival Raw flags: sec3=Y Item: 281200046; group id 427; item number 1062; lccId None; manufacturer id BGP Source form: Ent Tab; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $0.6883; ministry $0.2767 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00596426 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5677
Interchangeable products
Apo-Divalproex · DIN 02239699 · $0.2767 Mylan-Divalproex · DIN 02458934 · $0.2767
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00596426
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, ETHOSUXIMIDE, LAMOTRIGINE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

VALPROATE SODIUM

· 5 products · General benefit · strengths: 50mg/mL · O/L

VALPROIC ACID

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 250mg, 500mg · Cap, Ent Cap

VIGABATRIN

· 3 products · Temporary benefit (2), Limited Use, codes 136 (1) · strengths: 500mg/Sachet, 500mg · Pd for Oral Sol, Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

LAMOTRIGINE

· 28 products · General benefit · strengths: 25mg, 100mg, 150mg · Tab

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free)

PRIMIDONE

· 4 products · General benefit (2), Listed, not a benefit (2) · strengths: 125mg, 250mg · Tab

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: simple or complex absence seizures
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: VALPROATE SODIUM VALPROATE SODIUM · General benefit Indications DEPAKENE (valproic acid oral solution) is indicated for: • use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. PM: https://pdf.hres.ca/dpd_pm/00084557.PDF; date 2026-04-30; DIN 00443832; fetched 2026-09-10 Product monograph VALPROIC ACID · Listed, not a benefit (2), General benefit (3) (valproic acid) are indicated for: • use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. PM: https://pdf.hres.ca/dpd_pm/00083584.PDF; date 2026-02-23; DIN 02230768; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1. Indications EPIVAL® (divalproex sodium delayed-release tablets) is indicated for: Epilepsy • use as sole or adjunctive therapy in the treatment of simple or complex absence seizures, including petit mal, and is useful in primary generalized seizures with tonic-clonic manifestations. • use adjunctively in patients with multiple seizure types which include either absence or tonic-clonic seizures. In accordance with the International Classification of Seizures, simple absence is defined as a very brief clouding of the sensorium or loss of consciousness (lasting usually 2 to 15 seconds), accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. Acute Mania • the treatment of the manic episodes associated with bipolar disorder (DSM-III-R). The safety and efficacy of EPIVAL for long-term use in mania, that is for more than 3 weeks, have not been evaluated in controlled trials. See 2 Contraindications, and 7 Hepatic/Biliary/Pancreatic, Serious or Fatal Hepatotoxicity for statement regarding serious or fatal hepatic dysfunction. 1.1. Pediatrics Pediatrics (< 18 years… https://pdf.hres.ca/dpd_pm/00084579.PDF PM date: 2026-04-30 Source product: EPIVAL; DIN 00596418; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.